Stockreport

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics, Inc.  (HOWL) 
PDF – Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting – – Encouraging signs of cl [Read more]